The approval of the checkpoint inhibitor (ICI) ipilimumab, which targets the immunoinhibitory receptor cytotoxic T lymphocyte associated protein (CTLA-)4 for the treatment of metastatic melanoma, more than a decade ago initiated an era of considerable progress in melanoma treatment [2]. Here, CTLA4 is linked to melanoma.